BioNTech SE ADR (BNTX): Price and Financial Metrics

BioNTech SE ADR (BNTX): $137.19

-0.38 (-0.28%)

POWR Rating

Component Grades













Add BNTX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where BNTX ranks best; there it ranks ahead of 98.08% of US stocks.
  • BNTX's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • BNTX's current lowest rank is in the Growth metric (where it is better than 1.06% of US stocks).

BNTX Stock Summary

  • With a market capitalization of $32,778,431,854, BIONTECH SE has a greater market value than 93.71% of US stocks.
  • BNTX's current price/earnings ratio is 2.73, which is higher than merely 4.75% of US stocks with positive earnings.
  • As for revenue growth, note that BNTX's revenue has grown 136.56% over the past 12 months; that beats the revenue growth of 93.38% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to BIONTECH SE, a group of peers worth examining would be GOLD, SMMT, CKPT, UTSI, and HGEN.
  • BNTX's SEC filings can be seen here. And to visit BIONTECH SE's official web site, go to

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $137.19 52-week high $374.58
Prev. close $137.57 52-week low $117.08
Day low $135.51 Volume 508,300
Day high $138.56 Avg. volume 1,447,560
50-day MA $148.61 Dividend yield N/A
200-day MA $162.00 Market Cap 33.29B

BioNTech SE ADR (BNTX) Company Bio

BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.

BNTX Latest News Stream

Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream

Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

  • The European Union's drug regulator has started a rolling review of Pfizer (NYSE:PFE) and German partner BioNTech's (NASDAQ:BNTX) Omicron BA.4/5-subvariant adapted COVID-19 shot for use in children aged 5 to 11 years.
  • The European Medicines Agency (EMA) announced the update on Twitter on Monday.
  • A rolling review allows the regul...

    Seeking Alpha | October 3, 2022

10 Best COVID Stocks To Buy Now

In this article, we discuss 10 best COVID stocks to buy now. If you want to see more stocks in this selection, check out 5 Best COVID Stocks To Buy Now. In 2020, the COVID-19 pandemic was the primary driver of global uncertainty, making headlines around the world. The virus took a backseat only recently, […]

Yahoo | September 30, 2022

UPDATE 1-Around 3.2 mln Americans received updated COVID boosters last week -CDC

Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.

Yahoo | September 29, 2022

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

Yahoo | September 29, 2022

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

Yahoo | September 29, 2022

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo -1.00%
3-mo -19.36%
6-mo -17.85%
1-year -40.77%
3-year N/A
5-year N/A
YTD -45.75%
2021 216.24%
2020 140.61%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4852 seconds.